Back to search
FDAFDA · Food and drugs·Recall number D-0690-2021

Erythromycin Topical Gel, 2%, Net Wt. (a) 30 g,(NDC 52565-033-30) (b) 60 g,(NDC 52565-033-60) Rx Only, Manufactured by: Teligent Pharma, Inc. , Buena, NJ 08310,

Published July 28, 2021 · Recall initiated: June 22, 2021

Summary

FDA records drug Class III recall D-0690-2021, published July 28, 2021 and initiated June 22, 2021. Recalling firm: Teligent Pharma, Inc.; Status: Terminated; Reported quantity: 22,824 tubes; Lot: 1) NDC 52565-033-30 Lot 14010, Exp July 2021; 2) NDC 52565-033-60 Lot 13865, Exp June 2021; Lot 14011, Exp July 2021. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Impurities/Degradation Specifications

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Teligent Pharma, Inc.
Distributor
Nationwide
Lot
1) NDC 52565-033-30 Lot 14010, Exp July 2021; 2) NDC 52565-033-60 Lot 13865, Exp June 2021; Lot 14011, Exp July 2021.
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Erythromycin Topical Gel, 2%, Net Wt. (a) 30 g,(NDC 52565-033-30) (b) 60 g,(NDC 52565-033-60) Rx Only, Manufactured by: Teligent Pharma, Inc. , Buena, NJ 08310, recalled?

Yes. FDA published recall D-0690-2021 on July 28, 2021. Reported hazard: Failed Impurities/Degradation Specifications

What should I do if I have this product?

Voluntary: Firm initiated · Letter